Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults with Generalized Myasthenia Gravis (MAGIC)

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults with Generalized Myasthenia Gravis (MAGIC)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DNTH 103 (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MAGIC

    • Most Recent Events

    • 07 Nov 2024 According to a Dianthus Therapeutics media release, this Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing and company remains on track to report topline results in second half of 2025 (2H25).
    • 24 Sep 2024 According to a Hesperos media release, Human-on-a-Chip model validates the potential role of DNTH103 as a treatment for myasthenia gravis and supported Dianthus's FDA submission for its Phase II myasthenia gravis clinical trial.
    • 09 May 2024 According to a Dianthus Therapeutics media release, R&D expenses for the this quarter ended were $13.1 million, including $0.8 million of stock-based compensation, compared to $5.8 million for March 31, 2023, including $0.2 million of stock-based compensation. This increase in expenses was primarily driven by higher clinical, CMC costs and increased headcount to support DNTH103 Phase 1 and Phase 2 development, partially offset by lower pre-clinical costs.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top